Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer

Jeong Youp Park, Seung Woo Park, Jae Bock Chung, Jinsil Seong, Kyung Sik Kim, Woo Jung Lee, Si Young Song

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVES: Bile duct cancer is a rare malignancy with poor prognosis. We sought to determine the efficacy of concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. METHODS: Nineteen patients with unresectable extrahepatic bile duct cancer received doxifluridine (600 mg/m) daily, intravenous paclitaxel (50 mg/m) weekly (before radiotherapy), and radiotherapy of 4500 cGy for approximately 5 weeks. RESULTS: Local response rate which reflected the reopening of occluded bile duct was 89.5% (17 out of 19). In 6 cases (31.6%), overall response, which measured the change of tumor size, was achieved with this treatment. The longest survival time was 52 months, and median survival time was 14 months. One- and 2-year survival rates were 84.2% and 31.6%, respectively. One case of gastrointestinal bleeding and 1 case of grade III leukopenia occurred during the treatment. One patient could not finish the treatment because of poor general condition. CONCLUSIONS: Concurrent chemoradiotherapy with doxifluridine and paclitaxel seemed to produce a good clinical response without severe toxicity and improve survival rates in patients with extrahepatic bile duct cancer.

Original languageEnglish
Pages (from-to)240-245
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume29
Issue number3
DOIs
Publication statusPublished - 2006 Jun 1

Fingerprint

Bile Duct Neoplasms
Extrahepatic Bile Ducts
Chemoradiotherapy
Paclitaxel
Radiotherapy
Survival Rate
Survival
Leukopenia
Bile Ducts
Neoplasms
Therapeutics
Hemorrhage
doxifluridine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Park, Jeong Youp ; Park, Seung Woo ; Chung, Jae Bock ; Seong, Jinsil ; Kim, Kyung Sik ; Lee, Woo Jung ; Song, Si Young. / Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2006 ; Vol. 29, No. 3. pp. 240-245.
@article{d34d0dcd4adf4d9b9dfcefdc883ff569,
title = "Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer",
abstract = "OBJECTIVES: Bile duct cancer is a rare malignancy with poor prognosis. We sought to determine the efficacy of concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. METHODS: Nineteen patients with unresectable extrahepatic bile duct cancer received doxifluridine (600 mg/m) daily, intravenous paclitaxel (50 mg/m) weekly (before radiotherapy), and radiotherapy of 4500 cGy for approximately 5 weeks. RESULTS: Local response rate which reflected the reopening of occluded bile duct was 89.5{\%} (17 out of 19). In 6 cases (31.6{\%}), overall response, which measured the change of tumor size, was achieved with this treatment. The longest survival time was 52 months, and median survival time was 14 months. One- and 2-year survival rates were 84.2{\%} and 31.6{\%}, respectively. One case of gastrointestinal bleeding and 1 case of grade III leukopenia occurred during the treatment. One patient could not finish the treatment because of poor general condition. CONCLUSIONS: Concurrent chemoradiotherapy with doxifluridine and paclitaxel seemed to produce a good clinical response without severe toxicity and improve survival rates in patients with extrahepatic bile duct cancer.",
author = "Park, {Jeong Youp} and Park, {Seung Woo} and Chung, {Jae Bock} and Jinsil Seong and Kim, {Kyung Sik} and Lee, {Woo Jung} and Song, {Si Young}",
year = "2006",
month = "6",
day = "1",
doi = "10.1097/01.coc.0000217829.77404.22",
language = "English",
volume = "29",
pages = "240--245",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. / Park, Jeong Youp; Park, Seung Woo; Chung, Jae Bock; Seong, Jinsil; Kim, Kyung Sik; Lee, Woo Jung; Song, Si Young.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 29, No. 3, 01.06.2006, p. 240-245.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer

AU - Park, Jeong Youp

AU - Park, Seung Woo

AU - Chung, Jae Bock

AU - Seong, Jinsil

AU - Kim, Kyung Sik

AU - Lee, Woo Jung

AU - Song, Si Young

PY - 2006/6/1

Y1 - 2006/6/1

N2 - OBJECTIVES: Bile duct cancer is a rare malignancy with poor prognosis. We sought to determine the efficacy of concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. METHODS: Nineteen patients with unresectable extrahepatic bile duct cancer received doxifluridine (600 mg/m) daily, intravenous paclitaxel (50 mg/m) weekly (before radiotherapy), and radiotherapy of 4500 cGy for approximately 5 weeks. RESULTS: Local response rate which reflected the reopening of occluded bile duct was 89.5% (17 out of 19). In 6 cases (31.6%), overall response, which measured the change of tumor size, was achieved with this treatment. The longest survival time was 52 months, and median survival time was 14 months. One- and 2-year survival rates were 84.2% and 31.6%, respectively. One case of gastrointestinal bleeding and 1 case of grade III leukopenia occurred during the treatment. One patient could not finish the treatment because of poor general condition. CONCLUSIONS: Concurrent chemoradiotherapy with doxifluridine and paclitaxel seemed to produce a good clinical response without severe toxicity and improve survival rates in patients with extrahepatic bile duct cancer.

AB - OBJECTIVES: Bile duct cancer is a rare malignancy with poor prognosis. We sought to determine the efficacy of concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. METHODS: Nineteen patients with unresectable extrahepatic bile duct cancer received doxifluridine (600 mg/m) daily, intravenous paclitaxel (50 mg/m) weekly (before radiotherapy), and radiotherapy of 4500 cGy for approximately 5 weeks. RESULTS: Local response rate which reflected the reopening of occluded bile duct was 89.5% (17 out of 19). In 6 cases (31.6%), overall response, which measured the change of tumor size, was achieved with this treatment. The longest survival time was 52 months, and median survival time was 14 months. One- and 2-year survival rates were 84.2% and 31.6%, respectively. One case of gastrointestinal bleeding and 1 case of grade III leukopenia occurred during the treatment. One patient could not finish the treatment because of poor general condition. CONCLUSIONS: Concurrent chemoradiotherapy with doxifluridine and paclitaxel seemed to produce a good clinical response without severe toxicity and improve survival rates in patients with extrahepatic bile duct cancer.

UR - http://www.scopus.com/inward/record.url?scp=33744993844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744993844&partnerID=8YFLogxK

U2 - 10.1097/01.coc.0000217829.77404.22

DO - 10.1097/01.coc.0000217829.77404.22

M3 - Article

C2 - 16755176

AN - SCOPUS:33744993844

VL - 29

SP - 240

EP - 245

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -